These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 22721004

  • 1. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
    Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N.
    Mol Cancer; 2012 Jun 21; 11():42. PubMed ID: 22721004
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Blood; 2008 Apr 15; 111(8):4355-64. PubMed ID: 18268096
    [Abstract] [Full Text] [Related]

  • 3. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH.
    PLoS One; 2011 Apr 26; 6(4):e19164. PubMed ID: 21541334
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
    Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N.
    PLoS One; 2014 Apr 26; 9(11):e112318. PubMed ID: 25426931
    [Abstract] [Full Text] [Related]

  • 5. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
    Fei F, Stoddart S, Groffen J, Heisterkamp N.
    Mol Cancer Ther; 2010 May 26; 9(5):1318-27. PubMed ID: 20388735
    [Abstract] [Full Text] [Related]

  • 6. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 26; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 7. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 8. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
    Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY.
    Carcinogenesis; 2012 Feb 28; 33(2):285-93. PubMed ID: 22116466
    [Abstract] [Full Text] [Related]

  • 9. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
    Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM.
    Oncotarget; 2017 Apr 04; 8(14):23213-23227. PubMed ID: 28390196
    [Abstract] [Full Text] [Related]

  • 10. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
    Akahane D, Tauchi T, Okabe S, Nunoda K, Ohyashiki K.
    Cancer Sci; 2008 Jun 04; 99(6):1251-7. PubMed ID: 18429956
    [Abstract] [Full Text] [Related]

  • 11. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
    Gontarewicz A, Brümmendorf TH.
    Recent Results Cancer Res; 2010 Jun 04; 184():199-214. PubMed ID: 20072840
    [Abstract] [Full Text] [Related]

  • 12. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
    Wang LX, Wang JD, Chen JJ, Long B, Liu LL, Tu XX, Luo Y, Hu Y, Lin DJ, Lu G, Long ZJ, Liu Q.
    Sci Rep; 2016 Nov 08; 6():35533. PubMed ID: 27824120
    [Abstract] [Full Text] [Related]

  • 13. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
    Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE.
    Haematologica; 2015 Jul 08; 100(7):898-904. PubMed ID: 25887498
    [Abstract] [Full Text] [Related]

  • 14. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
    Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y, Zhuang X, Zhang F, Liu J, Leng F, Lang X, Bai Y, She M, Tu Z, Pan J, Ding K.
    J Med Chem; 2013 Feb 14; 56(3):879-94. PubMed ID: 23301703
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
    Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS.
    J Cell Mol Med; 2011 Oct 14; 15(10):2057-70. PubMed ID: 21091633
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
    Mu C, Wu X, Ma H, Tao W, Zhang G, Xia X, Shen J, Mai J, Sun T, Sun X, Arlinghaus RB, Shen H.
    Mol Cancer Ther; 2016 May 01; 15(5):899-910. PubMed ID: 26846820
    [Abstract] [Full Text] [Related]

  • 20. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
    Okabe S, Tauchi T, Ohyashiki K.
    Exp Hematol; 2010 Sep 01; 38(9):765-72. PubMed ID: 20471447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.